A Phase 1b Clinical Study on the Analgesic Effect of GIC-1001 and GIC-1002 on Visceral Pain Under Rectal Distension and Rectal Sensory Threshold Using the Barostat Method in Male and Female Healthy Volunteers.

Trial Profile

A Phase 1b Clinical Study on the Analgesic Effect of GIC-1001 and GIC-1002 on Visceral Pain Under Rectal Distension and Rectal Sensory Threshold Using the Barostat Method in Male and Female Healthy Volunteers.

Completed
Phase of Trial: Phase I

Latest Information Update: 12 Mar 2016

At a glance

  • Drugs GIC 1002 (Primary) ; Trimebutine 3-thiocarbamoylbenzenesulfonate (Primary)
  • Indications Procedural pain
  • Focus Therapeutic Use
  • Sponsors gIcare Pharma
  • Most Recent Events

    • 12 Mar 2016 Results (n=90) presented at the 117th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.
    • 12 Mar 2016 Results assessing the Analgesic efficacy of Gic-1001 and Gic-1002 presented at the 117th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.
    • 12 Jan 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top